Program Update December 13, 2012 Andrew J. Buckler, MS Principal Investigator, QI-Bench
Copyright 2004, D. P. MacKinnon 1 Methods to study Treatment Mechanisms of Action David P. MacKinnon NIDA Mechanisms Conference February 26 and 27, 2004.
Dr ... Journal
FDA’s Criteria for Evaluation of Red Blood Cell Products Ping He, M.D. Medical Officer Blood Products Advisory Committee 91st Meeting, May 1, 2008 Rockville.
PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington.
The POPPI 1 Example: Statistical Comments
FDA Regulatory Perspective RSV Vaccines Roberts
Acquired Resistance Patient Forum September 6, 2014 | Boston In ALK, ROS1 & EGFR Lung Cancers Clinical trial design and development of highly targeted.
James Cross, MS Pharmaceutical Outcomes Research and Policy Program University of Washington ----- Biobehavioral Cancer Fellows Day April 20, 2007 A risk-benefit.
1 Division of Oncology Drug Products Presentation NDA 21-649 Genasense (Oblimersen) for metastatic melanoma ODAC May 3, 2004.
